Dyne Therapeutics (NASDAQ:DYN) Receives Buy Rating from Guggenheim

Guggenheim reaffirmed their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a report issued on Wednesday,Benzinga reports. Guggenheim currently has a $50.00 price objective on the stock.

Several other analysts have also recently commented on the stock. Piper Sandler decreased their price target on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Robert W. Baird lowered their price target on Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating for the company in a report on Wednesday. BMO Capital Markets began coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They issued an “outperform” rating and a $50.00 target price on the stock. Evercore ISI assumed coverage on Dyne Therapeutics in a research note on Thursday, May 29th. They set an “outperform” rating and a $46.00 price objective on the stock. Finally, Chardan Capital reissued a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.93.

Dyne Therapeutics Trading Down 0.7%

DYN stock opened at $10.78 on Wednesday. Dyne Therapeutics has a 1 year low of $6.36 and a 1 year high of $47.45. The company has a fifty day simple moving average of $11.46 and a 200 day simple moving average of $14.84. The firm has a market cap of $1.23 billion, a PE ratio of -3.00 and a beta of 1.16.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.17). As a group, analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in DYN. Caitong International Asset Management Co. Ltd boosted its position in Dyne Therapeutics by 378.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,092 shares of the company’s stock valued at $32,000 after acquiring an additional 2,446 shares in the last quarter. Quarry LP purchased a new stake in shares of Dyne Therapeutics during the first quarter valued at approximately $47,000. GF Fund Management CO. LTD. bought a new stake in shares of Dyne Therapeutics in the 4th quarter worth $50,000. E Fund Management Co. Ltd. raised its position in Dyne Therapeutics by 16.2% in the 1st quarter. E Fund Management Co. Ltd. now owns 13,771 shares of the company’s stock worth $144,000 after buying an additional 1,923 shares during the last quarter. Finally, Optimize Financial Inc bought a new position in Dyne Therapeutics during the first quarter valued at approximately $154,000. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.